121 related articles for article (PubMed ID: 171574)
21. Halofenate: a potent inhibitor of normal and hypersensitive platelets.
Colman RW; Bennett JS; Sheridan JF; Cooper RA; Shattil SJ
J Lab Clin Med; 1976 Aug; 88(2):282-91. PubMed ID: 956686
[TBL] [Abstract][Full Text] [Related]
22. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Tattersall RB
Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
[No Abstract] [Full Text] [Related]
23. Letter: Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.
Daubresse JC; Luyckx AS; Lefebvre PJ
N Engl J Med; 1976 Mar; 294(11):613. PubMed ID: 1246250
[No Abstract] [Full Text] [Related]
24. Long-term efficacy of halofenate on serum triglyceride levels.
Aronow WS; Vicario MD; Moorthy K; King J; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1975 Dec; 18(6):855-61. PubMed ID: 813950
[No Abstract] [Full Text] [Related]
25. Alterations in the effects of warfarin in dogs by halofenate: an influence upon the kinetics of prothrombin.
Weintraub M; Griner PF
Thromb Diath Haemorrh; 1975 Nov; 34(2):445-54. PubMed ID: 1198407
[TBL] [Abstract][Full Text] [Related]
26. A clinical study of the metabolic effect of a new oral hypoglycemic agent: glipizide.
Iacono G; Ghionni A; Colucci M; Verde G; Caputo G
Int J Clin Pharmacol; 1974 Apr; 7(3):225-31. PubMed ID: 4850166
[No Abstract] [Full Text] [Related]
27. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
28. The effect of halofenate or halofenate free acid on human, rat and guinea pig platelet aggregation.
Minsker DH; Jordan PT; Kling P; MacMillan A; Hucker HB
Thromb Haemost; 1976 Apr; 35(2):358-63. PubMed ID: 989636
[TBL] [Abstract][Full Text] [Related]
29. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
[TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of a new sulfonylurea in maturity onset diabetes - glipizide (K-4024).
Bandisode MS; Boshell BR
Horm Metab Res; 1976 Mar; 8(2):89-91. PubMed ID: 770300
[TBL] [Abstract][Full Text] [Related]
31. Long-term effect of halofenate on serum lipids.
Aronow WS; Vangrow J; Pagano J; Khemka M; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
[No Abstract] [Full Text] [Related]
32. Biguanides. Mode of action and role in the up-to-date treatment of diabetes mellitus.
Fövényi J
Ther Hung; 1971; 19(2):43-8. PubMed ID: 5172874
[No Abstract] [Full Text] [Related]
33. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
Eaton RP; Oase R; Schade DS
Metabolism; 1976 Mar; 25(3):245-9. PubMed ID: 1250161
[TBL] [Abstract][Full Text] [Related]
34. Halofenate and clofibrate inhibition of pyruvate dehydrogenase from Fusarium culmorum.
Madhosingh C; Orr W
J Environ Sci Health B; 1985 Apr; 20(2):201-14. PubMed ID: 3998411
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
Domke A; Willms B
Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
[TBL] [Abstract][Full Text] [Related]
37. [Therapy of diabetes in adults using Glibornurid. Results and clinical studies].
Schöffling K; Mehnert H; Ewald W; Haupt E; Wicklmayr M; Beyer J; Nemeth N
Dtsch Med Wochenschr; 1973 May; 98(18):915-9. PubMed ID: 4633717
[No Abstract] [Full Text] [Related]
38. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Hutchison JC; Wilkinson WH
Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
[No Abstract] [Full Text] [Related]
39. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
[No Abstract] [Full Text] [Related]
40. [The influence of clofibrate on elevated serum lactate levels in diabetic patients treated with biguanides (author's transl)].
Vogelberg KH; Cicmir I; Heggen ME
Arzneimittelforschung; 1980; 30(4):683-5. PubMed ID: 7190412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
